Fig. 5

FOXC1 reverses RvD1/miR-138-mediated suppression of NSCLC cell growth and invasion. a. FOXC1 mRNA expression data were downloaded from the TCGA database containing 439 LUAC cancer tissues. The overall survival (OS) of patients with tumor expressing high vs. low FOXC1 was analyzed by the COX regression test. The relationship between FOXC1 and lymph node metastasis (N0-N3) was analyzed by Kruskal-Wallis test. b. Representative immunohistochemical images of LUSC and LUAC tissues stained with an anti-FOXC1 antibody. Representative in situ hybridization images of lung cancer tissues stained with a miR-138-5p antibody. Scale bars = 50 μm (40×). c. A549 cells were transfected with Con, miR-138-5p mimics, pCMV, or FOXC1-pCMV, and then subjected to cell growth and invasion assays. *P < 0.05, **P < 0.01 compared to Con group; ^##P < 0.01 compared to miR-138 group; ^$$P < 0.01, compared to FOXC1-overexpressed group. d. A549 cells were transfected with above, and then subjected to cell invasion assays. The transwell units were stained and photographed. High power views (200×) were selected randomly from each sample in a blind manner. e. A549 cells were transfected with Negcon, miR-138 inhibitor, siNC, or siFOXC1, and then subjected to cell growth assays (n = 4). **P < 0.01 compared to siNC group; ^##P < 0.01 compared to miR-138 inhibitor group. f. A549 cells were transfected with above reagents, and subjected to cell invasion assays, and high power views (200×) were selected. g. A549 cells were transfected with pCMV or FOXC1-pCMV, and subjected to cell growth assays (n = 4). **P < 0.01 compared to pCMV group; ^#P < 0.05, ^##P < 0.01 compared to pCMV+RvD1 200 μg/L group. ^$P < 0.05, ^$$P < 0.01 compared to FOXC1-overexpression group. h. A549 cells were treated as above and subjected to the invasion assays. The transwell units were stained and high power views (200×) were selected randomly from each sample in a blind manner